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of 0.68–0.88. Scores correlated significantly with frequency
of migraines in the past month and use of prophylactic
medications daily (both p  0.0001). Correlation of the
QOLWM and HDI total scores for the 728 people who
completed both questionnaires was 0.73. Item correlations
with the HDI total score were 0.47–0.67, demonstrating
external criterion validity. Additional studies are ongoing
to assess reproducibility and responsiveness.
CONCLUSIONS: These data demonstrate the psychomet-
ric properties of the QOLWM. The brief questionnaire may
be useful as a screening tool for clinicians to evaluate the im-
pact of migraine on individuals. The two-dimensional ap-
proach to patient-reported quality of life allows individuals
to weight the impact of both frequency and bothersomeness
of chronic migraines on multiple aspects of daily life.
SR4
LONGITUDINAL ASSESSMENT OF ASTHMA 
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OBJECTIVE: Describe relationships between changes in
work outcomes (WO) and changes in asthma severity
over a one-year period.
METHODS: This longitudinal study surveyed adults en-
rolled in a managed care organization using identical
mailed surveys. 106 respondents completed both the 1997
and 1998 questionnaires and reported working outside the
home. Self-reported WO included missed work days due
to asthma and work performance (WP) from the Func-
tional Status Questionnaire, a 6-item scale using a 4-point
Likert scale, transformed to a 100 point scale. A 4-week
time reference was used. Perceived severity was determined
by asking patients their perceived severity on a 5-point
scale from very mild to very severe; evaluated severity was
based on reported symptoms matched to national guide-
lines. Respondents were grouped by change in asthma se-
verity: improvement; no change; or decline of at least one
severity category. Analysis included descriptive statistics,
paired Student’s t-test, and McNemer’s test.
RESULTS: Initially, respondent’s mean age was 44.4
(10.9) years; 72 (68.6%) were female; 76.7% had an an-
nual family income of 
$40,000; 96.2% were Caucasian;
and 76.4% had some college education or more; 42.9%
perceived their asthma severity as very mild or mild,
38.1% moderate, and 19.1% as severe or very severe.
Based on symptoms, 32.4% were classified as intermittent
mild, 28.6% mild persistent, 36.2% moderate, and 2.9%
severe asthma. WP scores changed in the expected direc-
tion based on changes in asthma severity: no change in
perceived severity (n  58) had no significant change in
WP score (91.3  13.0 versus 92.9  12.4, p  0.52); im-
provement in perceived severity (less severe, n  17) had
improved WP scores (91.8  7.9 versus 94.4  9.4, p 
0.30); and worsening of perceived severity (n  26) had a
decline in WP score (94.4  8 versus 91.3  10.9, p 
0.07). WP score trends were similar based on evaluated se-
verity. There were no significant differences in changes in
the number of respondents who reported missing work.
CONCLUSIONS: Changes in WP are related to asthma
severity. The measure of missed days work is less consis-
tently related.
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OBJECTIVES: To study the incidence of medical events
and resource utilisation in patients treated for severe cancer
pain with strong opioids with the general practitioner (GP).
METHODS: We analyzed data on 2,323 cancer patients
who switched from a weak to a strong opioid. Patients
started either on TTS Fentanyl (TTS: N  270), Immedi-
ate Release Morphine (IR: N  1,909) or Sustained Re-
lease Morphine (SR: N  144). We compared the medi-
cal events during their pain treatment, the number of
patients receiving concomitant medication and the num-
ber of GP visits. A descriptive analysis was performed as
well as relative risks (RR) calculated, adjusting for rele-
vant co-variates.
RESULTS: The groups were comparable for age (avg. 68
yrs). There were more female patients in the TTS group
(61.5%) compared to 48.1% and 49.3% for IR and SR,
respectively. Median duration of cancer prior to the start
of strong opioids was 7.1 months for TTS, 6 for IR and
5.3 for SR. Mean duration of treatment: 68 days for TTS,
97 for IR and 92 for SR. No differences in concomitant
illnesses were observed except for cancer types with sig-
nificantly more GI and fewer lung cancers in the TTS
group. Compared to TTS, patients on IR had more con-
stipation (RR 1.49: 95% CI 1.14–1.94), more nausea
and vomiting (RR 1.43: 95% CI 1.09–1.88) and more
cardiac events (RR 1.95: 95% CI 1.15–3.29), while SR
patients differed from TTS only with respect to cardiac
events (RR 2.79: 95% CI 1.49–5.22). IR patients had
also a higher rate of hospitalizations (RR 1.95: 95% CI
1.14–3.31) and GP visits (RR 1.21: 95% CI 0.98–1.49).
Fewer TTS patients consumed additional pain medica-
tion, laxatives as well as antibiotics and CNS medication.
CONCLUSION: This analysis of GP derived observa-
tional data indicate that TTS Fentanyl results in a lower
consumption of medication and other health care re-
sources compared to morphine treated cancer patients.
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OBJECTIVES: To compare observational data with a
large clinical study (MUCOSA) which showed that miso-
prostol reduced NSAID complication rates by 40% in pa-
tients with arthritis. To measure the cost of prescribing,
endoscopy and hospitalizations for patients receiving non-
steroidal anti-inflammatory drugs (NSAIDs) and estimate
the cost-effectiveness of misoprostol in routine practice.
METHODS: A cohort study using all patients in the Tay-
side region that received NSAIDs and anti-ulcer drugs be-
tween 1989 and 1995. Thirty-day treatment was esti-
mated from the cost of the NSAID plus endoscopies plus
hospitalization for GI events. Costs of hospitalizations
and endoscopic procedures were obtained from Scottish
Information and Statistics Division for 1997.
RESULTS: Among 54,807 eligible patients the risk ad-
justed rates of hospitalization for gastrointestinal diag-
noses were 50% lower on Arthrotec (a fixed combination
of misoprostol and diclofenac) than on diclofenac alone.
Statistically significant risk factors were: a prior history
of gastrointestinal events (p  0.001), a prior history of
cardiovascular events (p  0.001), increasing age (p 
0.001), social deprivation score (p  0.072), concurrent
exposure to anti-ulcer drugs (p  0.001) or steroids (p 
0.001) and type and dose of NSAID (p  0.001 and p 
0.047 respectively). Only nabumatone had a lower event
rate than Arthrotec, but at a higher expected cost. Ar-
throtec had lower 30 day treatment and complication
costs than diclofenac alone in high risk patients (e.g., £52
vs £86 for a patient aged 80–89 with a prior history of
GI events) but not in low risk patients (e.g., £16.50 vs
£15 for a patient aged 50–59 with no prior GI events).
CONCLUSIONS: There was close agreement between
this observational study and the MUCOSA study on the
extent to which the prophylactic use of misoprostol re-
duced NSAID associated gastrointestinal complications.
The combination of misoprostol with diclofenac should
reduce thirty day treatment and complication costs in
high risk patients, in comparison with diclofenac alone.
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OBJECTIVES: To investigate the cost-effectiveness of
high dose IV omeprazole as an adjuvant therapy to endo-
scopic hemostasis for prevention of early ulcer rebleeding
from a hospital perspective. A randomized, placebo-con-
trolled clinical trial was conducted previously in a local
hospital to study the effects of high dose IV omeprazole in-
fusion on patient outcomes after endoscopic ulcer hemo-
stasis. Although the interim data suggested that IV ome-
prazole significantly decreased the rate of early rebleeding
that occurred 72 hours after therapy, the cost implication
of this therapy has not been examined.
METHODS: The data of 157 patients who completed the
above study was analyzed. The percentages of patients who
experienced early rebleeding were obtained from medical
records. The health care resources consumed by each pa-
tient during the first 72 hours post endoscopic hemostasis
were also retrieved from their records and studied.
RESULTS: Four of 80 (5%) patients in the omeprazole
group and 17 of 77 (22%) patients from the placebo
group had rebleeding within 72 hrs after endoscopy and
required further treatment. The treatment cost within 72
hours post endoscopy of the IV omeprazole group was
lower than that of the placebo group (HK$1312 per pa-
tient vs. $3223 per patient, 1 US  7.8 HK). The cost-
effectiveness ratios for the omeprazole group and placebo
group were $9,946 and $12,821, respectively, per early re-
bleeding episode prevented.
CONCLUSIONS: High dose omeprazole is more cost-
effective in preventing early ulcer rebleeding than placebo
after endoscopic hemostasis.
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OBJECTIVES: To determine the economical and clinical
impact of pharmacists’ interventions in ambulatory care
within the context of a prescribing error of Nonsteroidal
Anti-Inflammatory Drugs (NSAIDs).
METHOD: A national survey was carried out in 900
town pharmacies during 12 weeks to record all prescrip-
tions with an anomaly like contraindication, interaction
which could be dangerous for the patient. We used a deci-
sion analysis to compare two strategies, with or without a
systematic pharmacist’s intervention before a prescription
of NSAIDs. The outcome was upper gastrointestinal side
effects of NSAID therapy (peptic ulcer and complications)
and we used a prescribing errors rate varying between
0,5% to 2% to estimate the costs savings and to measure
the occurrence of peptic ulcer avoided. Computer simula-
tion was performed with Tree Age 3.0.
RESULTS: 446 cases of NSAIDs prescription errors were
notified including combination of NSAIDs, NSAIDs over-
dose and NSAIDs prescription with risk factors like peptic
